Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset

Схожие документы

• Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non‐small‐cell lung cancer with or without prior crizotinib therapy
  по: Hida, Toyoaki, et al.
  Опубликовано: (2016)
• Phase II study of ceritinib in alectinib‐pretreated patients with anaplastic lymphoma kinase‐rearranged metastatic non‐small‐cell lung cancer in Japan: ASCEND‐9
  по: Hida, Toyoaki, et al.
  Опубликовано: (2018)
• The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer
  по: Friboulet, Luc, et al.
  Опубликовано: (2014)
• Alectinib can replace crizotinib as standard first-line therapy for ALK-positive lung cancer
  по: Uemura, Takehiro, et al.
  Опубликовано: (2017)
• Osimertinib for Japanese patients with T790M‐positive advanced non‐small‐cell lung cancer: A pooled subgroup analysis
  по: Hirashima, Tomonori, et al.
  Опубликовано: (2019)